Chu Ming-Chia, Mao Wei-Chang, Wu Han-Fang, Chang Yun-Chi, Lu Ting-I, Lee Chi-Wei, Chung Yueh-Jung, Hsieh Tsung-Han, Chang Hsun-Shuo, Chen Yih-Fung, Lin Chia-Hsien, Tang Chih-Wei, Lin Hui-Ching
Department and Institute of Physiology, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Department of Psychiatry, Cheng-Hsin General Hospital, Taipei, Taiwan.
Pharmacol Rep. 2023 Oct;75(5):1200-1210. doi: 10.1007/s43440-023-00525-w. Epub 2023 Sep 11.
The pathological form of synaptic plasticity, ischemic long-term potentiation (iLTP), induced by oxygen and glucose deprivation (OGD), is implicated in the acute phase of stroke with the potentiation of N-methyl-D-aspartate receptor (NMDAR). While there has been widespread attention on the excitatory system, a recent study reported that γ-aminobutyric acid (GABA)ergic system is also involved in iLTP. Valproic acid (VPA), a histone deacetylase inhibitor, protects against ischemic damage. However, whether VPA regulates early phase plasticity in ischemic stroke remains unknown. The present study aims to investigate the potential role and mechanism of VPA in ischemic stroke.
A brief exposure of OGD on the hippocampal slices and the induction of photothrombotic ischemia (PTI) were used as ex vivo and in vivo models of ischemic stroke, respectively.
Using extracellular recordings, iLTP was induced in the hippocampal Schaffer collateral pathway following OGD exposure. VPA treatment abolished hippocampal iLTP via GABA receptor enhancement and extracellular signal-regulated kinase (ERK) phosphorylation. Administration of VPA reduced brain infarct volume and motor dysfunction in mice with PTI. Moreover, VPA protected against ischemic injury by upregulating the GABAergic system and ERK phosphorylation, as well as by reducing of matrix metalloproteinase in a PTI-induced ischemic stroke model.
Together, this study revealed the protection of VPA in ex vivo OGD-induced pathological form of neuroplasticity and in vivo PTI-induced brain damage and motor dysfunction through rescuing GABAergic deficiency and the pathological hallmarks of ischemia.
由氧糖剥夺(OGD)诱导的突触可塑性病理形式,即缺血性长时程增强(iLTP),与中风急性期N-甲基-D-天冬氨酸受体(NMDAR)的增强有关。虽然兴奋性系统受到了广泛关注,但最近一项研究报道γ-氨基丁酸(GABA)能系统也参与了iLTP。丙戊酸(VPA)是一种组蛋白去乙酰化酶抑制剂,可预防缺血性损伤。然而,VPA是否调节缺血性中风的早期可塑性仍不清楚。本研究旨在探讨VPA在缺血性中风中的潜在作用和机制。
分别将海马切片短暂暴露于OGD以及诱导光血栓性缺血(PTI)作为缺血性中风的离体和体内模型。
通过细胞外记录,在OGD暴露后海马体的谢弗侧支通路中诱导出了iLTP。VPA治疗通过增强GABA受体和细胞外信号调节激酶(ERK)磷酸化消除了海马体iLTP。给予VPA可减少PTI小鼠的脑梗死体积和运动功能障碍。此外,在PTI诱导的缺血性中风模型中,VPA通过上调GABA能系统和ERK磷酸化以及减少基质金属蛋白酶来预防缺血性损伤。
总之,本研究揭示了VPA在离体OGD诱导的神经可塑性病理形式以及在体内PTI诱导的脑损伤和运动功能障碍中的保护作用,其机制是挽救GABA能缺乏和缺血的病理特征。